New drug trial aims to outsmart lung Cancer's resistance
Disease control
Ongoing
This study is testing a drug called Lazertinib as the first treatment for people with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to see how well the drug controls the cancer, how safe it is, and to understand…
Phase: PHASE2 • Sponsor: Se-Hoon Lee • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC